Verrica Pharmaceuticals Q3 2026 Earnings Date & Estimates

Verrica Pharmaceuticals (NASDAQ:VRCA) is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases with limited or inadequate therapeutic options. The company’s work centers on topical therapies designed for use in dermatology practices and other healthcare settings.

Verrica’s lead product, YCANTHE (cantharidin), is a topical solution approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children two years of age and older. Molluscum contagiosum is a contagious viral skin infection that commonly causes small, raised lesions. YCANTHE is applied by healthcare professionals and is intended to provide an office-based treatment option.

Founded in 2013, Verrica is based in West Chester, Pennsylvania, and primarily serves the U.S. dermatology market. In addition to YCANTHE, the company has pursued a pipeline of topical therapies for other dermatological conditions, including treatments aimed at common warts. Verrica’s leadership has included Chief Executive Officer Ted White, who has experience in the biopharmaceutical and dermatology sectors.